{"product_id":"abnormal-psychology-isbn-9781119362289","title":"Abnormal Psychology","description":"\u003cp\u003e\u003cb\u003e\u003ci\u003eAbnormal Psychology: The Science and Treatment of Psychological Disorders\u003c\/i\u003e\u003c\/b\u003e consists of a balance and blending of research and clinical application, the use of paradigms as an organizing principle, and involving the learner in the kinds of real-world problem solving engaged in by clinicians and scientists. Students learn that psychopathology is best understood by considering multiple perspectives and that these varying perspectives provide the clearest accounting of the causes of these disorders as well as the best possible treatments.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 Introduction and Historical Overview 1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003ePsychological Disorders and Stigmas 2\u003c\/p\u003e \u003cp\u003eDefining Psychological Disorder 6\u003c\/p\u003e \u003cp\u003ePersonal Distress 6\u003c\/p\u003e \u003cp\u003eDisability and Dysfunction 6\u003c\/p\u003e \u003cp\u003eViolation of Social Norms 7\u003c\/p\u003e \u003cp\u003eHistory of Psychopathology 8\u003c\/p\u003e \u003cp\u003eSupernatural Explanations 8\u003c\/p\u003e \u003cp\u003eEarly Biological Explanations 9\u003c\/p\u003e \u003cp\u003eThe Dark Ages: Back to the Supernatural 9\u003c\/p\u003e \u003cp\u003eDevelopment of Asylums 10\u003c\/p\u003e \u003cp\u003eThe Evolution of Contemporary Thought 13\u003c\/p\u003e \u003cp\u003eBiological Approaches 14\u003c\/p\u003e \u003cp\u003ePsychological Approaches 15\u003c\/p\u003e \u003cp\u003eHave We Learned From History? 23\u003c\/p\u003e \u003cp\u003eThe Mental Health Professions 25\u003c\/p\u003e \u003cp\u003eSummary 26\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Current Paradigms in Psychopathology 28\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eThe Genetic Paradigm 28\u003c\/p\u003e \u003cp\u003eBehavior Genetics 30\u003c\/p\u003e \u003cp\u003eMolecular Genetics 31\u003c\/p\u003e \u003cp\u003eGene–Environment Interactions 33\u003c\/p\u003e \u003cp\u003eEvaluating the Genetic Paradigm 33\u003c\/p\u003e \u003cp\u003eThe Neuroscience Paradigm 35\u003c\/p\u003e \u003cp\u003eNeurons and Neurotransmitters 35\u003c\/p\u003e \u003cp\u003eStructure and Function of the Human Brain 36\u003c\/p\u003e \u003cp\u003eThe Neuroendocrine System 39\u003c\/p\u003e \u003cp\u003eThe Immune System 39\u003c\/p\u003e \u003cp\u003eNeuroscience Approaches to Treatment 39\u003c\/p\u003e \u003cp\u003eEvaluating the Neuroscience Paradigm 40\u003c\/p\u003e \u003cp\u003eThe Cognitive Behavioral Paradigm 41\u003c\/p\u003e \u003cp\u003eInfluences from Behavior Therapy 41\u003c\/p\u003e \u003cp\u003eCognitive Science 42\u003c\/p\u003e \u003cp\u003eThe Role of the Unconscious 43\u003c\/p\u003e \u003cp\u003eCognitive Behavior Therapy 43\u003c\/p\u003e \u003cp\u003eEvaluating the Cognitive Behavioral Paradigm 45\u003c\/p\u003e \u003cp\u003eFactors That Cut Across Paradigms 45\u003c\/p\u003e \u003cp\u003eEmotion and Psychopathology 46\u003c\/p\u003e \u003cp\u003eSociocultural Factors and Psychopathology 47\u003c\/p\u003e \u003cp\u003eInterpersonal Factors and Psychopathology 49\u003c\/p\u003e \u003cp\u003eSummary 54\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Diagnosis and Assessment 56\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eCornerstones of Diagnosis and Assessment: Reliability and Validity 57\u003c\/p\u003e \u003cp\u003eReliability 57\u003c\/p\u003e \u003cp\u003eValidity 58\u003c\/p\u003e \u003cp\u003eDiagnosis 60\u003c\/p\u003e \u003cp\u003eThe Diagnostic System of the American Psychiatric Association: DSM-5 60\u003c\/p\u003e \u003cp\u003eSpecific Criticisms of the DSM 66\u003c\/p\u003e \u003cp\u003eGeneral Criticisms of Diagnosing Psychological Disorders 69\u003c\/p\u003e \u003cp\u003ePsychological Assessment 70\u003c\/p\u003e \u003cp\u003eClinical Interviews 71\u003c\/p\u003e \u003cp\u003eAssessment of Stress 73\u003c\/p\u003e \u003cp\u003ePersonality Tests 75\u003c\/p\u003e \u003cp\u003eIntelligence Tests 78\u003c\/p\u003e \u003cp\u003eBehavioral and Cognitive Assessment 79\u003c\/p\u003e \u003cp\u003eDirect Observation of Behavior 79\u003c\/p\u003e \u003cp\u003eSelf-Monitoring 80\u003c\/p\u003e \u003cp\u003eCognitive-Style Questionnaires 80\u003c\/p\u003e \u003cp\u003eNeurobiological Assessment 81\u003c\/p\u003e \u003cp\u003eBrain Imaging: \"Seeing\" the Brain 81\u003c\/p\u003e \u003cp\u003eNeuropsychological Assessment 84\u003c\/p\u003e \u003cp\u003ePsychophysiological Assessment 85\u003c\/p\u003e \u003cp\u003eA Cautionary Note About Neurobiological Assessment 85\u003c\/p\u003e \u003cp\u003eCultural and Ethnic Diversity and Assessment 86\u003c\/p\u003e \u003cp\u003eCultural Bias in Assessment 87\u003c\/p\u003e \u003cp\u003eStrategies for Avoiding Cultural Bias in Assessment 88\u003c\/p\u003e \u003cp\u003eSummary 89\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Research Methods in Psychopathology 91\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eScience, Theory, and Hypotheses 92\u003c\/p\u003e \u003cp\u003eResearch Designs in Psychopathology 92\u003c\/p\u003e \u003cp\u003eThe Case Study 92\u003c\/p\u003e \u003cp\u003eThe Correlational Method 94\u003c\/p\u003e \u003cp\u003eThe Experiment 101\u003c\/p\u003e \u003cp\u003eOne Example of Experimental Research: Treatment Outcome Research 105\u003c\/p\u003e \u003cp\u003eDefining the Treatment Condition 106\u003c\/p\u003e \u003cp\u003eDefining Control Groups 108\u003c\/p\u003e \u003cp\u003eDefining a Sample 109\u003c\/p\u003e \u003cp\u003eAssessing and Implementing Treatments in the Real World 109\u003c\/p\u003e \u003cp\u003eAnalogues in Psychopathology Research 112\u003c\/p\u003e \u003cp\u003eIntegrating the Findings of Multiple Studies 114\u003c\/p\u003e \u003cp\u003eReplication 114\u003c\/p\u003e \u003cp\u003eMeta-Analysis 116\u003c\/p\u003e \u003cp\u003eSummary 118\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Mood Disorders 120\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eClinical Descriptions and Epidemiology of Depressive Disorders 121\u003c\/p\u003e \u003cp\u003eMajor Depressive Disorder 122\u003c\/p\u003e \u003cp\u003ePersistent Depressive Disorder 122\u003c\/p\u003e \u003cp\u003eEpidemiology and Consequences of Depressive Disorders 123\u003c\/p\u003e \u003cp\u003eClinical Descriptions and Epidemiology of Bipolar Disorders 127\u003c\/p\u003e \u003cp\u003eBipolar I Disorder 128\u003c\/p\u003e \u003cp\u003eBipolar II Disorder 128\u003c\/p\u003e \u003cp\u003eCyclothymic Disorder 128\u003c\/p\u003e \u003cp\u003eEpidemiology and Consequences of Bipolar Disorders 129\u003c\/p\u003e \u003cp\u003eEtiology of Mood Disorders 131\u003c\/p\u003e \u003cp\u003eGenetic Factors 131\u003c\/p\u003e \u003cp\u003eNeurotransmitters 133\u003c\/p\u003e \u003cp\u003eNeural Regions Involved in Emotion and Reward Processing 134\u003c\/p\u003e \u003cp\u003eCortisol Dysregulation 136\u003c\/p\u003e \u003cp\u003eSocial Factors in Depression: Childhood Adversity, Life Events, and Interpersonal Difficulties 137\u003c\/p\u003e \u003cp\u003ePsychological Factors in Depression 139\u003c\/p\u003e \u003cp\u003eSocial and Psychological Factors in Bipolar Disorder 142\u003c\/p\u003e \u003cp\u003eTreatment of Mood Disorders 144\u003c\/p\u003e \u003cp\u003ePsychological Treatment of Depression 144\u003c\/p\u003e \u003cp\u003ePsychological Treatment of Bipolar Disorder 147\u003c\/p\u003e \u003cp\u003eBiological Treatment of Mood Disorders 148\u003c\/p\u003e \u003cp\u003eSuicide 152\u003c\/p\u003e \u003cp\u003eEpidemiology of Suicide and Suicide Attempts 153\u003c\/p\u003e \u003cp\u003eRisk Factors for Suicide 155\u003c\/p\u003e \u003cp\u003ePreventing Suicide 157\u003c\/p\u003e \u003cp\u003eSummary 159\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Anxiety Disorders 161\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eEmotions of Anxiety and Fear 162\u003c\/p\u003e \u003cp\u003eClinical Descriptions of the Anxiety Disorders 163\u003c\/p\u003e \u003cp\u003eSpecific Phobias 164\u003c\/p\u003e \u003cp\u003eSocial Anxiety Disorder 165\u003c\/p\u003e \u003cp\u003ePanic Disorder 167\u003c\/p\u003e \u003cp\u003eAgoraphobia 167\u003c\/p\u003e \u003cp\u003eGeneralized Anxiety Disorder 168\u003c\/p\u003e \u003cp\u003eComorbidity in Anxiety Disorders 169\u003c\/p\u003e \u003cp\u003eGender and Cultural Factors in the Anxiety Disorders 170\u003c\/p\u003e \u003cp\u003eGender 170\u003c\/p\u003e \u003cp\u003eCulture 170\u003c\/p\u003e \u003cp\u003eCommon Risk Factors Across the Anxiety Disorders 172\u003c\/p\u003e \u003cp\u003eFear Conditioning 172\u003c\/p\u003e \u003cp\u003eGenetic Factors 174\u003c\/p\u003e \u003cp\u003eNeurobiological Factors: The Fear Circuit and the Activity of Neurotransmitters 175\u003c\/p\u003e \u003cp\u003ePersonality: Behavioral Inhibition and Neuroticism 176\u003c\/p\u003e \u003cp\u003eCognitive Factors 176\u003c\/p\u003e \u003cp\u003eEtiology of Specific Anxiety Disorders 179\u003c\/p\u003e \u003cp\u003eEtiology of Specific Phobias 179\u003c\/p\u003e \u003cp\u003eEtiology of Social Anxiety Disorder 180\u003c\/p\u003e \u003cp\u003eEtiology of Panic Disorder 181\u003c\/p\u003e \u003cp\u003eEtiology of Agoraphobia 183\u003c\/p\u003e \u003cp\u003eEtiology of Generalized Anxiety Disorder 184\u003c\/p\u003e \u003cp\u003eTreatments of the Anxiety Disorders 185\u003c\/p\u003e \u003cp\u003eCommonalities Across Psychological Treatments 185\u003c\/p\u003e \u003cp\u003ePsychological Treatments of Specific Anxiety Disorders 186\u003c\/p\u003e \u003cp\u003eMedications That Reduce Anxiety 189\u003c\/p\u003e \u003cp\u003eSummary 190\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Obsessive-Compulsive-Related and Trauma-Related Disorders 192\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eClinical Descriptions and Epidemiology of Obsessive-Compulsive and Related Disorders 193\u003c\/p\u003e \u003cp\u003eObsessive-Compulsive Disorder 193\u003c\/p\u003e \u003cp\u003eBody Dysmorphic Disorder 196\u003c\/p\u003e \u003cp\u003eHoarding Disorder 197\u003c\/p\u003e \u003cp\u003ePrevalence and Comorbidity of Obsessive-Compulsive and Related Disorders 198\u003c\/p\u003e \u003cp\u003eEtiology of the Obsessive-Compulsive and Related Disorders 199\u003c\/p\u003e \u003cp\u003eEtiology of Obsessive-Compulsive Disorder 200\u003c\/p\u003e \u003cp\u003eEtiology of Body Dysmorphic Disorder 201\u003c\/p\u003e \u003cp\u003eEtiology of Hoarding Disorder 201\u003c\/p\u003e \u003cp\u003eTreatment of the Obsessive-Compulsive and Related Disorders 203\u003c\/p\u003e \u003cp\u003eMedications 203\u003c\/p\u003e \u003cp\u003ePsychological Treatment 203\u003c\/p\u003e \u003cp\u003eDeep Brain Stimulation: A Treatment in Development for OCD 206\u003c\/p\u003e \u003cp\u003eClinical Description and Epidemiology of Posttraumatic Stress Disorder and Acute Stress Disorder 207\u003c\/p\u003e \u003cp\u003eEtiology of Posttraumatic Stress Disorder 210\u003c\/p\u003e \u003cp\u003eNature of the Trauma: Severity and the Type of Trauma Matter 211\u003c\/p\u003e \u003cp\u003eNeurobiology: The Hippocampus 211\u003c\/p\u003e \u003cp\u003eCoping 212\u003c\/p\u003e \u003cp\u003eTreatment of Posttraumatic Stress Disorder and Acute Stress Disorder 213\u003c\/p\u003e \u003cp\u003eMedication Treatment of PTSD 213\u003c\/p\u003e \u003cp\u003ePsychological Treatment of PTSD 214\u003c\/p\u003e \u003cp\u003ePsychological Treatment of Acute Stress Disorder 215\u003c\/p\u003e \u003cp\u003eSummary 216\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Dissociative Disorders and Somatic Symptom-Related Disorders 218\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eClinical Descriptions and Epidemiology of the Dissociative Disorders 219\u003c\/p\u003e \u003cp\u003eDepersonalization\/Derealization Disorder 220\u003c\/p\u003e \u003cp\u003eDissociative Amnesia 221\u003c\/p\u003e \u003cp\u003eDissociative Identity Disorder 224\u003c\/p\u003e \u003cp\u003eThe Epidemiology of Dissociative Disorders: Increases Over Time 225\u003c\/p\u003e \u003cp\u003eEtiology of DID 226\u003c\/p\u003e \u003cp\u003eThe Posttraumatic Model 227\u003c\/p\u003e \u003cp\u003eThe Sociocognitive Model 227\u003c\/p\u003e \u003cp\u003eTreatment of DID 229\u003c\/p\u003e \u003cp\u003eClinical Description of Somatic Symptom and Related Disorders 230\u003c\/p\u003e \u003cp\u003eClinical Description of Somatic Symptom Disorder 231\u003c\/p\u003e \u003cp\u003eClinical Description of Illness Anxiety Disorder 232\u003c\/p\u003e \u003cp\u003eClinical Description of Conversion Disorder 232\u003c\/p\u003e \u003cp\u003eEtiology of Somatic Symptom-Related Disorders 236\u003c\/p\u003e \u003cp\u003eNeurobiological Factors That Increase Awareness of and Distress Over Somatic Symptoms 236\u003c\/p\u003e \u003cp\u003eCognitive Behavioral Factors That Increase Awareness of and Distress Over Somatic Symptoms 238\u003c\/p\u003e \u003cp\u003eEtiology of Conversion Disorder 239\u003c\/p\u003e \u003cp\u003eTreatment of Somatic Symptom and Related Disorders 241\u003c\/p\u003e \u003cp\u003eSomatic Symptom Disorder and Illness Anxiety Disorder 241\u003c\/p\u003e \u003cp\u003eConversion Disorder 242\u003c\/p\u003e \u003cp\u003eSummary 243\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 Schizophrenia 245\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eClinical Descriptions of Schizophrenia 246\u003c\/p\u003e \u003cp\u003ePositive Symptoms 246\u003c\/p\u003e \u003cp\u003eNegative Symptoms 249\u003c\/p\u003e \u003cp\u003eDisorganized Symptoms 250\u003c\/p\u003e \u003cp\u003eOther Schizophrenia Spectrum Disorders 253\u003c\/p\u003e \u003cp\u003eEtiology of Schizophrenia 254\u003c\/p\u003e \u003cp\u003eGenetic Factors 254\u003c\/p\u003e \u003cp\u003eThe Role of Neurotransmitters 259\u003c\/p\u003e \u003cp\u003eConnectivity in the Brain 263\u003c\/p\u003e \u003cp\u003eEnvironmental Factors Influencing the Developing Brain 263\u003c\/p\u003e \u003cp\u003ePsychological Factors 264\u003c\/p\u003e \u003cp\u003eDevelopmental Factors 267\u003c\/p\u003e \u003cp\u003eTreatment of Schizophrenia 269\u003c\/p\u003e \u003cp\u003eMedications 270\u003c\/p\u003e \u003cp\u003ePsychological Treatments 273\u003c\/p\u003e \u003cp\u003eSummary 278\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Substance Use Disorders 280\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eOverview: Substance Use and the DSM-5 280\u003c\/p\u003e \u003cp\u003eClinical Descriptions: Alcohol, Tobacco, and Marijuana Use Disorders 282\u003c\/p\u003e \u003cp\u003eAlcohol Use Disorder 284\u003c\/p\u003e \u003cp\u003eTobacco Use Disorder 287\u003c\/p\u003e \u003cp\u003eMarijuana 290\u003c\/p\u003e \u003cp\u003eClinical Descriptions: Opioid, Stimulant, and Other Drug Use Disorders 294\u003c\/p\u003e \u003cp\u003eOpioids 295\u003c\/p\u003e \u003cp\u003eStimulants 298\u003c\/p\u003e \u003cp\u003eHallucinogens, Ecstasy, and PCP 301\u003c\/p\u003e \u003cp\u003eEtiology of Substance Use Disorders 303\u003c\/p\u003e \u003cp\u003eGenetic Factors 304\u003c\/p\u003e \u003cp\u003eNeurobiological Factors 305\u003c\/p\u003e \u003cp\u003ePsychological Factors 307\u003c\/p\u003e \u003cp\u003eSociocultural Factors 310\u003c\/p\u003e \u003cp\u003eTreatment of Substance Use Disorders 313\u003c\/p\u003e \u003cp\u003eTreatment of Alcohol Use Disorder 313\u003c\/p\u003e \u003cp\u003eTreatments for Smoking 316\u003c\/p\u003e \u003cp\u003eTreatment of Drug Use Disorders 318\u003c\/p\u003e \u003cp\u003ePrevention of Substance Use Disorders 323\u003c\/p\u003e \u003cp\u003eSummary 324\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 Eating Disorders 326\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eClinical Descriptions of Eating Disorders 327\u003c\/p\u003e \u003cp\u003eAnorexia Nervosa 327\u003c\/p\u003e \u003cp\u003eBulimia Nervosa 331\u003c\/p\u003e \u003cp\u003ePhysical Consequences of Bulimia Nervosa 332\u003c\/p\u003e \u003cp\u003eBinge Eating Disorder 333\u003c\/p\u003e \u003cp\u003eEtiology of Eating Disorders 338\u003c\/p\u003e \u003cp\u003eGenetic Factors 338\u003c\/p\u003e \u003cp\u003eNeurobiological Factors 338\u003c\/p\u003e \u003cp\u003eCognitive Behavioral Factors 341\u003c\/p\u003e \u003cp\u003eSociocultural Factors 343\u003c\/p\u003e \u003cp\u003eOther Factors Contributing to the Etiology of Eating Disorders 347\u003c\/p\u003e \u003cp\u003eTreatment of Eating Disorders 349\u003c\/p\u003e \u003cp\u003eMedications 349\u003c\/p\u003e \u003cp\u003ePsychological Treatment of Anorexia Nervosa 350\u003c\/p\u003e \u003cp\u003ePsychological Treatment of Bulimia Nervosa 350\u003c\/p\u003e \u003cp\u003ePsychological Treatment of Binge Eating Disorder 352\u003c\/p\u003e \u003cp\u003ePreventive Interventions for Eating Disorders 353\u003c\/p\u003e \u003cp\u003eSummary 354\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 Sexual Disorders 356\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eSexual Norms and Behavior 357\u003c\/p\u003e \u003cp\u003eGender and Sexuality 359\u003c\/p\u003e \u003cp\u003eThe Sexual Response Cycle 360\u003c\/p\u003e \u003cp\u003eClinical Descriptions of Sexual Dysfunctions 362\u003c\/p\u003e \u003cp\u003eDisorders Involving Sexual Interest, Desire, and Arousal 363\u003c\/p\u003e \u003cp\u003eOrgasmic Disorders 365\u003c\/p\u003e \u003cp\u003eSexual Pain Disorder 366\u003c\/p\u003e \u003cp\u003eEtiology of Sexual Dysfunctions 367\u003c\/p\u003e \u003cp\u003eBiological Factors 368\u003c\/p\u003e \u003cp\u003ePsychosocial Factors 368\u003c\/p\u003e \u003cp\u003eTreatments of Sexual Dysfunctions 370\u003c\/p\u003e \u003cp\u003ePsychoeducation 371\u003c\/p\u003e \u003cp\u003eCouples Therapy 371\u003c\/p\u003e \u003cp\u003eCognitive Interventions 372\u003c\/p\u003e \u003cp\u003eSensate Focus 372\u003c\/p\u003e \u003cp\u003eTreatments for Specific Sexual Dysfunctions 372\u003c\/p\u003e \u003cp\u003eClinical Descriptions of the Paraphilic Disorders 373\u003c\/p\u003e \u003cp\u003eFetishistic Disorder 375\u003c\/p\u003e \u003cp\u003ePedophilic Disorder and Incest 376\u003c\/p\u003e \u003cp\u003eVoyeuristic Disorder 378\u003c\/p\u003e \u003cp\u003eExhibitionistic Disorder 378\u003c\/p\u003e \u003cp\u003eFrotteuristic Disorder 378\u003c\/p\u003e \u003cp\u003eSexual Sadism and Masochism Disorders 378\u003c\/p\u003e \u003cp\u003eEtiology of the Paraphilic Disorders 380\u003c\/p\u003e \u003cp\u003eNeurobiological Factors 380\u003c\/p\u003e \u003cp\u003eChildhood Sexual Abuse 380\u003c\/p\u003e \u003cp\u003ePsychological Factors 380\u003c\/p\u003e \u003cp\u003eTreatments and Community Prevention for the Paraphilic Disorders 381\u003c\/p\u003e \u003cp\u003eStrategies to Enhance Motivation 382\u003c\/p\u003e \u003cp\u003eCognitive Behavioral Treatment 382\u003c\/p\u003e \u003cp\u003eBiological Treatments 382\u003c\/p\u003e \u003cp\u003eBalancing Efforts to Protect the Public Against Civil Liberties for Those with Paraphilias 383\u003c\/p\u003e \u003cp\u003eSummary 384\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 Disorders of Childhood 386\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eClassification and Diagnosis of Childhood Disorders 387\u003c\/p\u003e \u003cp\u003eExternalizing Disorders: ADHD and Conduct Disorder 388\u003c\/p\u003e \u003cp\u003eAttention-Deficit\/Hyperactivity Disorder 388\u003c\/p\u003e \u003cp\u003eConduct Disorder 395\u003c\/p\u003e \u003cp\u003eInternalizing Disorders: Depression and Anxiety Disorders 403\u003c\/p\u003e \u003cp\u003eDepression 403\u003c\/p\u003e \u003cp\u003eAnxiety 409\u003c\/p\u003e \u003cp\u003eSpecific Learning Disorder and Intellectual Disability 413\u003c\/p\u003e \u003cp\u003eDyslexia: A Type of Specific Learning Disorder 413\u003c\/p\u003e \u003cp\u003eIntellectual Disability 416\u003c\/p\u003e \u003cp\u003eAutism Spectrum Disorder 421\u003c\/p\u003e \u003cp\u003eClinical Descriptions, Prevalence, and Prognosis of Autism Spectrum Disorder 421\u003c\/p\u003e \u003cp\u003eEtiology of Autism Spectrum Disorder 425\u003c\/p\u003e \u003cp\u003eTreatment of Autism Spectrum Disorder 427\u003c\/p\u003e \u003cp\u003eSummary 428\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14 Late Life and Neurocognitive Disorders 430\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eAging: Myths, Problems, and Methods 431\u003c\/p\u003e \u003cp\u003eMyths About Late Life 432\u003c\/p\u003e \u003cp\u003eThe Problems Experienced in Late Life 433\u003c\/p\u003e \u003cp\u003eResearch Methods in the Study of Aging 433\u003c\/p\u003e \u003cp\u003ePsychological Disorders in Late Life 435\u003c\/p\u003e \u003cp\u003ePrevalence Estimates of Psychological Disorders in Late Life 435\u003c\/p\u003e \u003cp\u003eMethodological Issues in Estimating the Prevalence of Psychopathology 437\u003c\/p\u003e \u003cp\u003eTreatment 437\u003c\/p\u003e \u003cp\u003eDementia 438\u003c\/p\u003e \u003cp\u003eAlzheimer’s Disease 440\u003c\/p\u003e \u003cp\u003eFrontotemporal Dementia 444\u003c\/p\u003e \u003cp\u003eVascular Dementia 445\u003c\/p\u003e \u003cp\u003eDementia with Lewy Bodies 445\u003c\/p\u003e \u003cp\u003eTreatments for Dementia 446\u003c\/p\u003e \u003cp\u003eDelirium 449\u003c\/p\u003e \u003cp\u003eEtiology of Delirium 451\u003c\/p\u003e \u003cp\u003eTreatment of Delirium 451\u003c\/p\u003e \u003cp\u003eSummary 452\u003c\/p\u003e \u003cp\u003e\u003cb\u003e15 Personality Disorders 454\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eThe DSM-5 Approach to Classification 455\u003c\/p\u003e \u003cp\u003eProblems with the DSM-5 Approach to Personality Disorders 457\u003c\/p\u003e \u003cp\u003eAlternative DSM-5 Model for Personality Disorders 459\u003c\/p\u003e \u003cp\u003eCommon Risk Factors Across the Personality Disorders 461\u003c\/p\u003e \u003cp\u003eClinical Description and Etiology of the Odd\/Eccentric Cluster 463\u003c\/p\u003e \u003cp\u003eParanoid Personality Disorder 463\u003c\/p\u003e \u003cp\u003eSchizoid Personality Disorder 464\u003c\/p\u003e \u003cp\u003eSchizotypal Personality Disorder 464\u003c\/p\u003e \u003cp\u003eClinical Description and Etiology of the Dramatic\/Erratic Cluster 466\u003c\/p\u003e \u003cp\u003eAntisocial Personality Disorder and Psychopathy 466\u003c\/p\u003e \u003cp\u003eBorderline Personality Disorder 470\u003c\/p\u003e \u003cp\u003eHistrionic Personality Disorder 473\u003c\/p\u003e \u003cp\u003eNarcissistic Personality Disorder 473\u003c\/p\u003e \u003cp\u003eClinical Description and Etiology of the Anxious\/Fearful Cluster 476\u003c\/p\u003e \u003cp\u003eAvoidant Personality Disorder 476\u003c\/p\u003e \u003cp\u003eDependent Personality Disorder 477\u003c\/p\u003e \u003cp\u003eObsessive-Compulsive Personality Disorder 478\u003c\/p\u003e \u003cp\u003eTreatment of Personality Disorders 479\u003c\/p\u003e \u003cp\u003eTreatment of Schizotypal Personality Disorder and Avoidant Personality Disorder 481\u003c\/p\u003e \u003cp\u003eTreatment of Borderline Personality Disorder 481\u003c\/p\u003e \u003cp\u003eSummary 483\u003c\/p\u003e \u003cp\u003e\u003cb\u003e16 Legal and Ethical Issues 485\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eCriminal Commitment 486\u003c\/p\u003e \u003cp\u003eThe Insanity Defense 487\u003c\/p\u003e \u003cp\u003eCurrent Insanity Pleas 489\u003c\/p\u003e \u003cp\u003eCompetency to Stand Trial 492\u003c\/p\u003e \u003cp\u003eInsanity, Intellectual Disability, and Capital Punishment 496\u003c\/p\u003e \u003cp\u003eCivil Commitment 498\u003c\/p\u003e \u003cp\u003ePreventive Detention and Problems in the Prediction of Dangerousness 499\u003c\/p\u003e \u003cp\u003eProtection of the Rights of People with Psychological Disorders 500\u003c\/p\u003e \u003cp\u003eEthical Dilemmas in Therapy and Research 505\u003c\/p\u003e \u003cp\u003eEthical Restraints on Research 506\u003c\/p\u003e \u003cp\u003eInformed Consent 507\u003c\/p\u003e \u003cp\u003eConfidentiality and Privileged Communication 508\u003c\/p\u003e \u003cp\u003eSummary 509\u003c\/p\u003e \u003cp\u003eAppendix: DSM-5 Diagnoses A-1\u003c\/p\u003e \u003cp\u003eGlossary G-1\u003c\/p\u003e \u003cp\u003eReferences R-1\u003c\/p\u003e \u003cp\u003eName Index N-1\u003c\/p\u003e \u003cp\u003eSubject Index S-1\u003c\/p\u003e \u003cp\u003e\u003cb\u003eDr. Ann Kring\u003c\/b\u003e is a professor of Psychology at the University of California-Berkeley and is the director of the Emotion and Social Interaction Laboratory. She received her PhD. from State University of New York at Stony Brook. Dr.Kring's broad research interests are in emotion and psychopathology. Specific interests include the emotional features of schizophrenia, assessing negative symptoms in schizophrenia, and the linkage between cognition and emotion in schizophrenia. In addition, Dr. Kring studies emotion in healthy individuals, with a focus on individual differences in expressive behavior, gender differences in emotion, and the linkages between personality, social context, and emotion.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSheri L. Johnson\u003c\/b\u003e, PhD, is Associate Professor of Psychology and Psychiatry at the University of Miami. Over the past decade, she has conducted research on psychosocial facets of bipolar disorder. Her work has been funded by the National Alliance for Research on Schizophrenia and Depression and by the National Institute of Mental Health, and her findings have been published in a number of journals, including the \u003ci\u003eJournal of Abnormal Psychology\u003c\/i\u003e and the \u003ci\u003eAmerican Journal of Psychiatry\u003c\/i\u003e.\u003c\/p\u003e","brand":"Wiley","offers":[{"title":"Default Title","offer_id":47988651262181,"sku":"NP9781119362289","price":111.0,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781119362289.jpg?v=1761781120","url":"https:\/\/k12savings.com\/es\/products\/abnormal-psychology-isbn-9781119362289","provider":"K12savings","version":"1.0","type":"link"}